Felipe Alexis Avalos-Salgado, Laura Gonzalez-Lopez, Sergio Gonzalez-Vazquez, Juan Manuel Ponce-Guarneros, Aline Priscilla Santiago-Garcia, Edna Lizeth Amaya-Cabrera, Reynaldo Arellano-Cervantes, J Ahuixotl Gutiérrez-Aceves, Miriam Fabiola Alcaraz-Lopez, Cesar Arturo Nava-Valdivia, Fabiola Gonzalez-Ponce, Norma Alejandra Rodriguez-Jimenez, Miguel Angel Macias-Islas, Edgar Ricardo Valdivia-Tangarife, Ana Miriam Saldaña-Cruz, Ernesto German Cardona-Muñoz, Jorge Ivan Gamez-Nava
Background: Rheumatoid arthritis (RA) in elderly population represents a challenge for physicians in terms of therapeutic management. Methotrexate (MTX) is the first-line treatment among conventional synthetic-disease-modifying anti-rheumatic drugs (cs-DMARDs); however, it is often associated with adverse events (AEs). Therefore, the objective of this study was to identify the incidence and risk factors of MTX discontinuation due to AEs in elderly patients with RA in a long-term retrospective cohort study. Methods: Clinical sheets from elderly RA patients taking MTX from an outpatient rheumatology consult in a university centre were reviewed...
March 24, 2024: Journal of Clinical Medicine